| Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. | |
| | |
MedLine Citation:
|
PMID: 22850787 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity, including reversal of inflammation-mediated loss of sight, hearing and organ function. This approach can therefore be effective in treating common conditions such as post-infarction heart failure, and trials targeting a broad spectrum of new indications are underway. So far, three IL-1-targeted agents have been approved: the IL-1 receptor antagonist anakinra, the soluble decoy receptor rilonacept and the neutralizing monoclonal anti-IL-1β antibody canakinumab. In addition, a monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α antibody are in clinical trials. |
| | |
Authors:
|
Charles A Dinarello; Anna Simon; Jos W M van der Meer |
Related Documents
:
|
22690157 - Biomarker genes for detecting estrogenic activity of endocrine disruptors via estrogen ... 11564427 - Nmda or non-nmda receptor antagonists attenuate increased fos expression in spinal dors... 12204197 - Glial cell plasticity in sensory ganglia induced by nerve damage. 2354357 - 5-hydroxytryptamine immunoreactive varicosities in the lamprey spinal cord have no syna... 9024637 - Novel mechanisms of rtk signal generation. 11319837 - Translocation of the il-1 receptor to focal adhesions is regulated through the c-termin... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Nature reviews. Drug discovery Volume: 11 ISSN: 1474-1784 ISO Abbreviation: Nat Rev Drug Discov Publication Date: 2012 Aug |
Date Detail:
|
Created Date: 2012-08-01 Completed Date: 2012-10-10 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 101124171 Medline TA: Nat Rev Drug Discov Country: England |
Other Details:
|
Languages: eng Pagination: 633-52 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of Colorado Denver, Aurora, Colorado 80045, USA. cdinare333@aol.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anti-Inflammatory Agents / pharmacology*, therapeutic use Antibodies, Monoclonal / pharmacology, therapeutic use Autoimmune Diseases / drug therapy, immunology, physiopathology Drug Delivery Systems Drug Design Humans Inflammation / drug therapy*, immunology, physiopathology Interleukin 1 Receptor Antagonist Protein / pharmacology, therapeutic use Interleukin-1 / antagonists & inhibitors*, metabolism Receptors, Interleukin-1 / antagonists & inhibitors*, metabolism Recombinant Fusion Proteins / pharmacology, therapeutic use Severity of Illness Index |
| Grant Support | |
ID/Acronym/Agency:
|
AI‑15614/AI/NIAID NIH HHS; AR‑45584/AR/NIAMS NIH HHS; CA‑04 6934/CA/NCI NIH HHS; R01 AI015614/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Interleukin 1 Receptor Antagonist Protein; 0/Interleukin-1; 0/Receptors, Interleukin-1; 0/Recombinant Fusion Proteins; 0/canakinumab; 0/rilonacept |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Revisiting lab-on-a-chip technology for drug discovery.
Next Document: Strong presence of the high grain protein content allele of NAM-B1 in Fennoscandian wheat.